Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cholesteryl 14-methylhexadecanoate as a possible marker of malignant tumours.

Oncology reports·2011
Same author

Activity of cholesterol-esterifying enzymes from rat liver cytosol is affected by malignant growth.

Oncology reports·2011
Same author

Alterations of cholesteryl ester metabolism characteristic for cancer.

Oncology reports·2011
Same author

Effect of short-term maximal exercise on BNP plasma levels in healthy individuals.

Physiological research·2009
Same author

[Will the therapy of chronic heart failure be guided by plasma levels of natriuretic peptides?].

Casopis lekaru ceskych·2009
Same author

[To treat or not to treat with statins patients with chronic heart failure?].

Vnitrni lekarstvi·2009

Related Experiment Video

Updated: Jun 8, 2026

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

[Anaemia in chronic heart failure].

J Hradec1

  • 1III. interní klinika 1. Iékarské fakulty UK a VFN Praha. jhradec@vfn.cz

Vnitrni Lekarstvi
|September 18, 2010
PubMed
Summary

Anemia in chronic heart failure and kidney disease is common and increases mortality risk. While erythropoiesis-stimulating agents can improve anemia, the TREAT study showed increased cerebrovascular events, highlighting safety concerns.

Area of Science:

  • Nephrology
  • Cardiology
  • Hematology

Context:

  • Anemia frequently co-exists with chronic heart failure (CHF) and chronic kidney disease (CKD).
  • Anemia in these conditions is a significant predictor of increased morbidity and mortality.
  • Multifactorial causes include reduced erythropoietin production, iron deficiency, and fluid retention.

Purpose:

  • To review the role of anemia in CHF and CKD and discuss treatment strategies.
  • To evaluate the efficacy and safety of erythropoiesis-stimulating agents (ESAs) in managing anemia in these patient populations.
  • To highlight findings from key clinical trials, including the TREAT and RED-HF studies.

Summary:

  • Treatment strategies involve stimulating erythropoiesis with ESAs (e.g., darbepoetin alfa) and iron substitution, preferably intravenous.

Related Experiment Videos

Last Updated: Jun 8, 2026

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

  • Previous small-scale studies suggested ESAs improved exertion tolerance and quality of life in CHF patients.
  • The TREAT study (n>4000) found darbepoetin alfa did not impact cardiovascular/renal events but increased cerebrovascular events in CKD patients with diabetes.

    • Impact:

    • Findings raise concerns about ESA safety, particularly regarding cerebrovascular events.
    • The ongoing RED-HF study aims to clarify the impact of anemia treatment on patient prognosis in CHF.
    • Optimal management of anemia in CHF and CKD requires careful consideration of risks and benefits.